First Quarter 2025 Summary Net income available to common shareholders of $4.2 million in Q1 2025, compared to $2.7 million in Q4 2024Diluted earnings per share of $0.43 in Q1 2025, compared to $0.28 in Q4 2024Net interest income of $17.5 million in Q1 2025, compared to $16.9 million in Q4 2024Net interest margin increased 16 basis points from 2.45% in Q4 2024 to 2.61% in Q1 2025Other real estate owned ("OREO") decreased $31.5 million from $35.9 million in Q4 2024 to $4.4 million in Q1 2025 due to the sale ...

WYOMISSING, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (“GLPI” or the “Company”) today announced financial results for the quarter ended March 31, 2025. Financial Highlights Three Months Ended March 31,(in millions, except per share data) 2025 2024Total Revenue $395.2 $376.0Income from Operations $258.8 $257.6Net Income <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bot ...

(All amounts in U.S. dollars) Q1 2025 revenue and adjusted EPS* above the high end of our guidance ranges;Raising 2025 annual outlook TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world's most innovative companies, today announced financial results for the quarter ended March 31, 2025 (Q1 2025). Q1 2025 Highlights Revenue: $2.65 billion, increased 20% compared to $2.21 billion for fir ...

Exosome-Based ExoPTEN Targets Three High-Value Nerve Injury IndicationsTORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries is presenting new data at the 2025 International Society for Extracellular Vesicles (ISEV) Annual Meeting being held in Vienna April 24-27. The ISEV presentation will feature ...

-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 CaMMouflage r/r MM Phase 1 dose escalation dataset expected to includ ...

Core Viewpoint - Apollo Commercial Real Estate Finance, Inc. reported a net income of $0.16 per diluted share and distributable earnings of $0.24 per diluted share for the first quarter of 2025, reflecting the impact of elevated repayments and capital deployment of $650 million [1][2]. Financial Performance - Net income attributable to common stockholders per diluted share was $0.16 for the quarter ended March 31, 2025 [1]. - Distributable Earnings per diluted share was $0.24 for the same period, which is a non-GAAP financial measure [1][4]. - The Company recorded no realized losses in the consolidated statement of operations during the three months ended March 31, 2025 [7]. Capital Deployment - The Company deployed $650 million in capital during the first quarter of 2025, focusing on redeploying capital into newly originated loans [2]. Dividend Policy - As a REIT, the Company is required to distribute at least 90% of its taxable income annually, and it intends to pay dividends in an amount equal to its net taxable income over time, subject to board authorization [5]. Company Overview - Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that primarily originates, acquires, invests in, and manages performing commercial first mortgage loans and related debt investments [10]. - The Company is externally managed by ACREFI Management, LLC, a subsidiary of Apollo Global Management, which had approximately $751 billion in assets under management as of December 31, 2024 [10].

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced that, following the merger with Cyclo Therapeutics, Bill Conkling will be stepping down as CEO and assuming an advisory role wit ...

PHOENIX, April 24, 2025 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that it will participate in the following investor conferences in the upcoming month: Barclays Americas Select Franchise ConferenceDate: May 6, 2025Location: London, United Kingdom Oppenheimer 20th Annual Industrial Growth ConferenceDate: May 7, 2025Location: Virtual Bank of America Industrials, Transportation & Airlines Key ...

ST. PETERSBURG, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”) the insurance holding company of American Coastal Insurance Company (“AmCoastal”), announced today that it expects to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the close of the market, and will conduct its quarterly conference call at 5:00 p.m. ET. The conference call will include li ...

FORT WORTH, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Farmer Bros. Co. (NASDAQ: FARM), a leading roaster, wholesaler and distributor of coffee, tea and allied products, announced today it will publish its fiscal third quarter 2025 financial results for the period ended March 31, 2025 with the filing of its 10-Q and the issuing of its earnings results release, both of which will be posted on the Investor Relations section of its website after the close of market on Thursday, May 8. The company will also host ...